Document is current
Any future updates will be listed below
-
Authors
Lakshman, Arjun https://orcid.org/0000-0001-8915-2382
Painuly, Utkarsh
Rajkumar, S. Vincent https://orcid.org/0000-0002-5862-1833
Ketterling, Rhett P.
Kapoor, Prashant
Greipp, Patricia T.
Gertz, Morie A.
Buadi, Francis K.
Lacy, Martha Q.
Dingli, David
Dispenzieri, Angela
Fonder, Amie L.
Hayman, Suzanne R.
Hobbs, Miriam A.
Gonsalves, Wilson I.
Hwa, Yi Lisa
Leung, Nelson https://orcid.org/0000-0002-5651-1411
Go, Ronald S. https://orcid.org/0000-0002-8284-3495
Lin, Yi
Kourelis, Taxiarchis V.
Warsame, Rahma
Lust, John A.
Russell, Stephen J.
Zeldenrust, Steven R.
Kyle, Robert A.
Kumar, Shaji K. https://orcid.org/0000-0001-5392-9284
-
Funding
Funding for this research was provided by:
Takeda Pharmaceuticals U.S.A.
Amgen
Celgene
Novartis Pharmaceuticals Corporation
Millenium
Pfizer
Janssen Pharmaceuticals
Amgen Inc. | Onyx Pharmaceuticals
AbbVie
Bristol-Myers Squibb
- License Information
-
More Information
Article History
Received: 26 August 2018
Revised: 11 February 2019
Accepted: 14 February 2019
First Online: 7 March 2019
Conflict of interest
: A.D. received research funding from Celgene, Millennium, Pfizer, and Janssen and travel grant from Pfizer. M.A.G. received consultancy from Millenium and honoraria from Celgene, Millenium, Onyx, Novartis, Smith Kline, Prothena, Ionis, and Amgen. M.Q.L. received research funding from Celgene. P.K. received research funding from Takeda, Celgene, and Amgen. S.K.K. received consultancy from Celgene, Millennium, Onyx, Janssen, and BMS and research funding from Celgene, Millennium, Novartis, Onyx AbbVie, Janssen, and BMS. The remaining authors declare no conflict of interests.
